araag2/HINT huggingface dataset:
Clinical trial NCT00687297 (phase 2, status: completed)
Conditions: lung cancer, non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: vandetanib induction, docetaxel, carboplatin, placebo, vandetanib maintenance
SMILES: COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed non-small cell lung cancer

          -  Advanced disease (stage IIIB disease [malignant pleural or pericardial effusion seen
             on CT or Chest X-ray, any N, M0] or stage IV disease [Any T, any N, M1: distant
             metastases]) that is primary or recurrent

          -  Measurable disease according to the RECIST criteria

          -  ECOG Performance Status 0 or 1

          -  Adequate organ function, as evidenced by ALL the following

          -  Absolute neutrophil count (ANC) ≥ 1500/mm³ and platelet count ≥ 100,000/mm³

          -  Hemoglobin ≥ 9 gm/dL

          -  Total bilirubin ≤ 1 X institutional ULN; if patient has Gilbert's disease, then
             patient must have isolated hyperbilirubinemia (e.g. no other liver function test
             abnormality), with maximum bilirubin ≤ 2 X institutional ULN.

          -  AST, ALT and alkaline phosphatase (Alk Phos) must be ≤ 1.5 ULN

          -  Creatinine ≤ 1.5 X institutional ULN or calculated creatinine clearance ≥ 60 ml/min

          -  Potassium between 4 mEq/L and institutional ULN (supplementation may be used),

          -  Calcium (ionized or adjusted for albumin)within institutional normal limits

          -  Magnesium within institutional normal limits (supplementation may be used)

          -  No prior cytotoxic chemotherapy or targeted therapy for advanced or metastatic disease
             (Prior adjuvant therapy for lung cancer allowed if completed > 1 year prior to
             registration)

          -  Able to take oral medication

        Exclusion Criteria:

          -  Myocardial infarction, superior vena caval syndrome, NYHA classification of heart
             disease ≥ 2 within the 3 months prior to entry

          -  History of an uncontrolled or recurrent ventricular, supraventricular or nodal
             arrhythmia that requires treatment

          -  Hypertension not controlled by medication

          -  Peripheral or sensory neuropathy > grade 1

          -  Known hypersensitivity to carboplatin or docetaxel

          -  Active infection
Clinical trial NCT00474383 (phase 2, status: completed)
Conditions: prostate neoplasms
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: abiraterone acetate, glucocorticoid
SMILES: [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma (cancer that begins in cells
             that line certain internal organs and that have secretory properties) of the prostate,
             but not with neuroendocrine differentiation or of small cell histology

          -  Before chemotherapy for prostate cancer with regimen(s) containing paclitaxel or
             docetaxel

          -  Documented prostate-specific antigen (PSA) progression according to PSA working group
             eligibility criteria with a PSA greater than 5 nanogram per milliliter (ng/mL)

          -  Ongoing androgen deprivation with serum testosterone level of less than 50 nanogram
             per deciliter (ng/dL)

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of less than or equal to
             2 (Karnofsky Performance Status greater than or equal 50 percentage)

        Exclusion Criteria:

          -  Active or uncontrolled autoimmune disease that may require corticosteroid therapy

          -  Serious or uncontrolled co-existent non-malignant disease, including active and
             uncontrolled infection

          -  Uncontrolled hypertension

          -  Clinically significant heart disease as evidenced by a myocardial infarction in the
             past 12 months, severe or unstable angina, or New York Heart Association (NYHA) Class
             III or IV heart disease (participants with a history of atherosclerotic vascular
             disease requiring coronary or peripheral artery bypass surgery may be enrolled
             provided the surgery occurred at least 2 years before to enrollment and after
             consultation with a cardiologist to insure that the disease is stable)

          -  History of gastrointestinal disorders (medical disorders or extensive surgery) which
             may interfere with the absorption of the study medication
Clinical trial NCT00554099 (phase 2, status: completed)
Conditions: diverticulitis
ICD codes: K57.00, K57.01, K57.12, K57.13, K57.20, K57.21, K57.32
Drugs: mesalamine, probiotic, placebo, antibiotic for diverticulitis
SMILES: NC1=CC(C(O)=O)=C(O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  A clinical diagnosis of acute diverticulitis

          -  Female patients must be postmenopausal (at least 1 year without spontaneous menses) or
             surgically sterile or have a negative urine pregnancy test and practice acceptable
             contraception (e.g., abstinence; oral, intramuscular, or implanted hormonal
             contraception [at least 3 months prior to enrollment]; 2-barrier methods [e.g.,
             condom, diaphragm, or spermicide]; intrauterine device or verbal report of partner
             with history of non-reversed vasectomy)

          -  Willing and able to participate in the study and provide a signed informed consent

        Exclusion Criteria:

          -  Presence of diverticular complications (e.g., fistula, abscess, obstruction,
             stenosis);

          -  Active or recent history (within 6 months) of a peptic ulcer;

          -  Prior history of irritable bowel syndrome (IBS), as determined by the Investigator;

          -  History of major abdominal surgery (as determined by the Investigator);

          -  History of GI surgery within 3 months of diagnosis of acute diverticulitis;

          -  History of immunocompromising disease, human immunodeficiency virus (HIV) infection,
             or acquired immunodeficiency syndrome (AIDS);

          -  If female patient, active or recent history of endometriosis or dysmenorrhea;

          -  Received a dose of a product that contains, or is metabolized to, mesalamine by any
             route within 4 weeks before the screening visit;
Clinical trial NCT00589979 (phase 2, status: completed)
Conditions: osteoarthritis of the knee
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: lidoderm (lidocaine 5% patch), placebo patch
SMILES: CCN(CC)CC(=O)NC1=C(C)C=CC=C1C, CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
Eligibility criteria:

        Key Inclusion criteria:

          -  Male or female patients ≥37 years with moderate-to-severe OA related pain in one knee

          -  Body mass index (BMI) ≤40 kg/m2

          -  Symptomatic OA of the index knee diagnosed with a functional capacity of II or III
             according to ACR criteria classification Note: Patients with symptomatic contralateral
             knee OA with persistent pain ≤2 cm on a 0-10 cm PI-NRS for ≥2 months will be allowed
             to participate.

          -  Unchanged dose of analgesic medication for OA for at least 4 weeks prior to screening
             and for the duration of the study

          -  Able and willing to complete all paper and e-diary assessments required by protocol

        Key Exclusion criteria:

          -  Pain in any joint other than the index joint that could interfere with the patient's
             assessment of pain in the index joint

          -  Compromised integrity of the intact, superficial skin layer

          -  A grade 1 or 4 Kellgren and Lawrence score on radiographic examination

          -  Recent injury to either knee causing pain and interference with daily activities (eg.
             walking)

          -  Recent surgery/procedure to either knee causing pain that could interfere with study
             assessments of pain, function, and QoL

          -  Known hypersensitivity or allergy to lidocaine, local anesthetics of the amide type,
             or any component of the product
Clinical trial NCT00676715 (phase 2, status: active, not recruiting)
Conditions: multiple sclerosis, relapsing-remitting
ICD codes: G35, G93.81, K74.1, Q85.1, G12.21, G12.23, M34.0
Drugs: placebo, ocrelizumab, avonex
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, O
Eligibility criteria:

        Inclusion Criteria:

          -  Ability to provide written informed consent and to be compliant with the schedule of
             protocol assessments

          -  Relapsing-remitting multiple sclerosis (MS)

          -  Ages 18-55 years inclusive

          -  For sexually active female and male participants of reproductive potential, use of
             reliable means of contraception

        Exclusion Criteria:

          -  Secondary or primary progressive multiple sclerosis at screening

          -  Incompatibility with MRI

          -  Contra-indications to or intolerance of oral or IV corticosteroids

          -  Known presence of other neurologic disorders

          -  Pregnancy or lactation

          -  Lack of peripheral venous access

          -  History of severe allergic or anaphylactic reactions to humanized or murine monoclonal
             antibodies

          -  Significant, uncontrolled disease, such as cardiovascular, pulmonary, renal, hepatic,
             endocrine or gastrointestinal

          -  Congestive heart failure

          -  Known active bacterial, viral, fungal, mycobacterial infection or other infection or
             any major episode of infection requiring hospitalization or treatment with IV
             antibiotics within 4 weeks prior to screening or oral antibiotics within 2 weeks prior
             to screening

          -  History or known presence of recurrent or chronic infection

          -  History of cancer, including solid tumors and hematological malignancies (except basal
             cell, in situ squamous cell carcinomas of the skin, and in situ carcinoma of the
             cervix of the uterus that have been excised and resolved)

          -  History of alcohol or drug abuse within 24 weeks prior to randomization

          -  History of or currently active primary or secondary immunodeficiency

          -  History of coagulation disorders

          -  Treatment with any investigational agent within 4 weeks of screening

          -  Receipt of a live vaccine within 6 weeks prior to randomization

          -  Incompatibility with Avonex use

          -  Previous treatment with rituximab

          -  Previous treatment with lymphocyte-depleting therapies except mitoxantrone

          -  Treatment with lymphocyte trafficking blockers within 24 weeks prior to randomization

          -  Treatment with beta interferons, glatiramer acetate, IV immunoglobulin,
             plasmapheresis, or immunosuppressive therapies within 12 weeks prior to randomization

          -  Systemic corticosteroid therapy within 4 weeks prior to randomization
Clinical trial NCT01024920 (phase 2, status: completed)
Conditions: carcinoma, renal cell
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: bibf 1120, sunitinib
SMILES: COC(=O)C1=CC=C2C(NC(=O)\C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1, CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
Eligibility criteria:

        Inclusion criteria:

          1. Patients with unresectable or metastatic Renal Cell Cancer, who have received no
             previous systemic anti-cancer treatment.

          2. Histological-confirmed diagnosis of renal cell cancer with clear cell component.

          3. Acceptable renal,liver,cardiovascular,bone marrow and other functions to allow
             sunitinib/BIBF 1120 treatment.

        Exclusion criteria:

          1. Patients unable to tolerate Sunitinib/BIBF 1120 treatment

          2. Treatment with other investigational drugs or participation in another clinical study
             within the past 4 weeks before start of therapy or concomitantly with this study.

          3. Patients unable to comply with the 1199.26 protocol.

          4. Pregnancy or breast feeding.

          5. Active alcohol or drug abuse.

          6. Women of child bearing potential, or men who are able to father a child, unwilling to
             use a medically acceptable form of contraception during the study period.
Clinical trial NCT00165503 (phase 2, status: terminated)
Conditions: pleural mesothelioma, malignant pleural mesothelioma
ICD codes: C45.9, C45.0, C45.1, C45.2, C45.7, C45.9, C45.0, C45.1, C45.2, C45.7
Drugs: cisplatin, sodium thiosulfate, alimta
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, OS(O)(=O)=S, [H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O
Reason stopped: 
    lack of acurral
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histopathologic confirmation of malignant pleural mesothelioma

          -  Patients who are able to tolerate surgical cytoreduction but unable to undergo
             extrapleural pneumonectomy due to poor cardiopulmonary reserve or tumor invasion or
             those with minimal disease

          -  Male on non-pregnant female

          -  18 years of age or older

          -  No evidence of spread outside the ipsilateral hemithorax by chest CT and chest MRI

          -  Ejection fraction > 45%

          -  Pre-operative WBC > 4K/uL

          -  Estimated life expectancy of at least 12 weeks

          -  Evidence of adequate renal and hepatic function

          -  Grossly normal contralateral pulmonary function with a chest radiograph and chest CT
             scan

          -  Karnofsky performance status of 70% or greater

          -  No evidence of disease progression by chest CT or chest MRI, obtained at 8 weeks
             following surgery

        Exclusion Criteria:

          -  Extended disease outside the ipsilateral hemithorax as determined on pre-operative
             radiographs or intraoperative findings

          -  Positive extrapleural nodes as determined by mediastinoscopy

          -  Gross disease (estimated thickness > 10mm at any intrathoracic location) present
             within the hemithorax after surgery

          -  Evidence of distant metastatic disease

          -  Severe non-malignant co-morbid disease, uncontrolled angina, myocardial infarction on
             the past 6 months, renal insufficiency, liver disease, pulmonary hypertension

          -  Pregnant or breast-feeding

          -  Serious concomitant systemic disorders

          -  Presence of active concomitant malignancy

          -  Psychiatric or addictive disorders, which would preclude informed consent

          -  Previous chemotherapy or radiation therapy for mesothelioma

          -  Chemotherapy or radiation therapy administered within 3 years for another malignancy
Clinical trial NCT01247818 (phase 2, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: ph-10 (0.002% rose bengal), ph-10 (0.005% rose bengal), ph-10 (0.01% rose bengal), vehicle
SMILES: OC(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C(O)=C(I)C=C12, OC(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C(O)=C(I)C=C12, OC(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C(O)=C(I)C=C12, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Men or women, age 18 or older.

          -  Presence of mild to moderate plaque psoriasis on the trunk or extremities (excluding
             palms, soles, scalp, and facial or intertriginous areas).

          -  Fitzpatrick skin type I-VI.

          -  Written informed consent by the subject or legal guardian.

        Exclusion Criteria:

          -  Female subjects of childbearing potential who are pregnant, attempting to conceive,
             not using effective contraception, or who are nursing an infant.

          -  Subjects who have received psoralen plus ultraviolet A (PUVA) therapy or systemic
             antipsoriatic therapy (immunosuppressants, cytostatics, corticosteroids) within 28
             days of study initiation (two weeks for methotrexate).

          -  Subjects who have received ultraviolet B (UVB) light therapy within 14 days of study
             initiation.

          -  Subjects who have received topical antipsoriatic therapy (including corticosteroids,
             tar, anthralin or Vitamin D analogs) to the study plaque areas within 14 days of study
             initiation.

          -  Subjects who have received agents posing a clinically significant risk of
             photosensitivity reaction within 5 half-lives of study initiation.

          -  Subjects who have received any approved or investigational biologic drug therapy for
             psoriasis within 90 days or 5 half-lives of study initiation.

          -  Subjects who have participated in a clinical research study within 28 days of study
             initiation.

          -  Subjects with a history of porphyria, systemic lupus erythematosus or xeroderma
             pigmentosum.

          -  Subjects with clinical conditions that, in the opinion of the Investigator may pose a
             health risk to the subject by being involved in the study or detrimentally affect
             regular follow-up of the subject.
Clinical trial NCT00157482 (phase 2, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ezetimibe, simvastatin
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes mellitus with stable antidiabetic treatment since at least three
             months

          -  Total cholesterol concentrations >135mg/dl and/or concomitant lipid lowering therapy
             with HMGCoA inhibitors

          -  Serum creatinine ≤1.5mg/dl

          -  Urinary albumin excretion rate < 200μg/min

          -  Written informed consent

        Exclusion Criteria:

          -  History of myocardial infarction, stroke or hospital admission for angina within the
             previous 6 months

          -  History of percutaneous transluminal coronary angioplasty or coronary artery bypass
             grafting

          -  Clinically manifest heart failure (grade III or above according to New York Heart
             Association criteria)

          -  Poor glycemic control (HbA1C >11%)

          -  Primary hyperlipidemia

          -  Uncontrolled thyroid diseases

          -  Infectious disease within 4 weeks of starting

          -  Acute liver disease or hepatic dysfunction

          -  Inflammatory muscle disease or evidence of muscle problems

          -  Concurrent treatment with systemic steroids, androgens, cyclosporin and other
             immunosuppressive drugs, fibrates, high-dose niacin or cholestyramine

          -  Pregnancy or lactating

          -  Women of childbearing potential without following a scientifically accepted form of
             contraception

          -  Life-threatening conditions or terminal concomitant diseases other than diabetes

          -  Specific contraindications or history of hypersensitivity to the study drugs or other
             statins

          -  Legal incapacity and/or other circumstances rendering the patient unable to understand
             the nature, scope and possible consequence of the trial

          -  Evidence of an uncooperative attitude

          -  Any evidence that patient will not be able to complete the trial follow-up
Clinical trial NCT00423137 (phase 2, status: completed)
Conditions: pulmonary disease, chronic obstructive, bronchitis, chronic
ICD codes: J44.9, J44.1, J44.0
Drugs: bibw 2948 bs, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  COPD smokers

          -  ages between 40 and 70

        Exclusion Criteria:

          -  Significant other diseases

          -  abnormal hematology

          -  abnormal liver function

          -  psychiatric disorders

          -  pulmonary obstruction

          -  asthma, allergic rhinitis

          -  dependance on oxygen

          -  patients with history of myocardial infarction

          -  patients with history of cancer

          -  women of child bearing potential

          -  antiplatelet or anticoagulation therapy
Clinical trial NCT00387660 (phase 2, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: carboplatin, irinotecan
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed small cell lung cancer, meeting 1 of the
             following criteria:

               -  Previously untreated metastatic or extensive disease

                    -  Malignant pleural effusion or multifocal lung disease is considered
                       metastatic or extensive disease

                    -  Prior radiotherapy allowed

               -  Recurrent disease

                    -  Limited, metastatic, or extensive disease

                    -  Relapsed after prior chemotherapy, excluding irinotecan hydrochloride

                         -  At least 90 days since prior chemotherapy

          -  Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 1 cm by
             physical examination or radiographic techniques

          -  Known brain metastases allowed

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Life expectancy ≥ 3 months

          -  White Blood Cells > 3,000/mm³

          -  Absolute neutrophil count ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Hemoglobin ≥ 9.0 g/dL

          -  Bilirubin ≤ 1.5 mg/dL

          -  SGOT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases present)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 3 months after
             completion of study treatment

          -  No medical disease that, in the opinion of the investigator, would preclude study
             treatment

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  At least 10 days since prior radiotherapy (including brain)

          -  No prior irinotecan hydrochloride

          -  At least 2 weeks since prior and no concurrent anticonvulsants

          -  No concurrent radiotherapy